PAI Pharma, owned by private equity firm Olympus Partners, announced on 12 November 2026 that it had acquired Nexus Pharmaceuticals, a US developer of complex injectable medicines for hospitals. Terms were not disclosed.
Why PAI Pharma (Olympus Partners portfolio company) is buying Nexus Pharmaceuticals, LLC
The acquisition expands PAI's sterile injectable range, building on its earlier purchase of Nivagen Pharmaceuticals, with Nexus products used in critical care, oncology and other hospital settings.
Market context
Olympus Partners acquired PAI Pharma in February 2025.
In the rankings
